0.21
0.21 (0%)
As of Oct 07, 2024
Renalytix Plc [RNLX]
Source:
Company Overview
Renalytix is focused on providing doctors around the world with a safe, reliable and effective tool to identify which patients are or are not in danger of losing significant kidney function and falling into kidney failure and may require long-term dialysis or a kidney transplant.
| Country | United States |
| Headquarters | london |
| Phone Number | 44 29 2071 0570 |
| Industry | services |
| CEO | James Mccullough |
| Website | www.renalytix.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.5 |
| Operating Profit | $-4.1 |
| Net Income | $-4.7 |
| Net Cash | $-3.8 |
Profit Ratios
| Gross Margin | $0.1 |
| Operating Margin | -784.1 |
| Profit as % of Revenues | -2.1% |
| Profit as % of Assets | -177.9% |
| Profit as % of Stockholder Equity | 41.8% |
Management Effectiveness
| Return on Equity | 41.8% |
| Return on Assets | -98.6% |
| Turnover Ratio | 19.6% |
| EBITA | $-4.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $4.8 |
| Total Liabilities | $16.1 |
| Operating Cash Flow | $-3.8 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $0 |
